Teva VAMPED-Up as it enrolls patients for Phase III multiple sclerosis trial
Posted Jan 14 2009 8:24pm
Teva enrolls patients for Phase III multiple sclerosis trial Source: MSRC - UK
Second large global phase III trial of oral laquinimod for Multiple Sclerosis starts enrollment
Laquinimod is a novel once-daily, orally administered immunomodulatory compound developed as a disease modifying treatment for multiple sclerosis (MS).
July 16, 2008 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced today that patients are being enrolled for the BRAVO Phase III pivotal trial.
BRAVO is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex® .
Source: MSRC - UK
Second large global phase III trial of oral laquinimod for Multiple Sclerosis starts enrollment
Laquinimod is a novel once-daily, orally administered immunomodulatory compound developed as a disease modifying treatment for multiple sclerosis (MS).
July 16, 2008 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced today that patients are being enrolled for the BRAVO Phase III pivotal trial.
BRAVO is a global, 24-month, double-blind study designed to evaluate the efficacy, safety and tolerability of the oral compound laquinimod versus placebo, and to provide risk-benefit data for laquinimod versus a currently available injectable treatment, Avonex® .
» Read More
===========================================
If you want to leave a comment to this article, you need to return-to
(or remain on) - this page
============================================